TABLE 1.

Prospective studies on HHV-6 reactivation after BMT

Detection methodaSamplebNo. of patientsIncidence of active HHV-6 infection (%)Observed diseasedHHV-6 variantReference
PCRPBMC, BALF4146Vascular endothelial damage, GVHDNot determined 389
PCRPBMC, plasma9242.5Myelosuppression, fever, delayed platelet and neutrophil engraftmentNot determined 177
PCRPBL2260Delayed platelet engraftmentB 266
PCRPBL, plasma6128Fever, engraftment failureB 62
PCRPBMC37Not givenDelayed platelet and granulocyte engraftmentB 421
PCRPBL, oral lavage fluid, urine5760Acute GVHD90% B, 10% A 428
PCR, IHCPBL, skin57Not givenGVHDNot determined 15
qPCRPBL, CSF7478Delayed platelet engraftmentNot determined 245
qPCRPBMC20cNot givenRash and fever (2/20)Not determined 79
VIPBMC8238RashB 447
VIPBMC22Not givenSkin rashNot determined 450
VIPBMC2646NoneB 197
VIPBMC and/or bone marrow2548Skin rashNot determined 456
  • a RT-PCR, reverse transcriptase PCR; qPCR, quantitative (real-time) PCR; VI, virus isolation; IHC, immunohistochemistry.

  • b PBL, peripheral blood lymphocytes; BALF, bronchoalveolar lavage fluid.

  • c Patients in this study were all HCMV seronegative.

  • d GVHD, graft-versus-host disease.